Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Against Arena Pharmaceuticals, Inc. (Nasdaq: ARNA)
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action lawsuits have been brought on behalf of purchasers of the securities of Arena Pharmaceuticals, Inc. (“Arena” or the “Company”) (Nasdaq: ARNA) between December 8, 2008 and September 16, 2010, inclusive (“Class Period”).
If you purchased Arena securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than November 19, 2010. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in this action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in this action.
Arena shareholders that wish to learn more about this action and how to seek appointment as lead plaintiff should visit Lieff Cabraser’s website at http://www.lieffcabraser.com/cases.php?CaseID=345 or contact attorney Sharon Lee toll free at (800) 541-7358.
Background on Arena Securities Class LitigationThe actions, pending in the United States District Court for the Southern District of California, were brought against Arena and certain of its officers for violations of federal securities laws. Arena, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral drugs that target G protein-coupled receptors. Arena’s principal drug under development is Lorcaserin, an experimental weight loss drug. The complaints allege that throughout the Class Period, defendants made materially false statements regarding Lorcaserin. Specifically, during the Class Period, defendants allegedly touted Lorcaserin’s purported efficacy, safety, and tolerability but failed to disclose certain health risks associated with the drug. On September 14, 2010, the Food and Drug Administration (“FDA”) issued a briefing document in advance of its advisory panel meeting that questioned the safety and efficacy of Lorcaserin and revealed, among other things, that the drug was associated with malignant tumors in rats. On this news, the price of Arena common stock fell $2.72 per share, or nearly 40 percent, to close at $4.13 per share on September 14, 2010. On September 16, 2010, the FDA advisory panel reportedly rejected Lorcaserin due to concerns with the drug’s efficacy and potential safety problems. On the following day, September 17, 2010, Arena’s stock fell another $1.75 per share, or approximately 47 percent, to close at $1.99 per share.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV